1. Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review
   Jia-jun Li et al, 2019, Frontiers in Pharmacology CrossRef
2. 18F-Labeled dihydropyridines via Hantzsch reaction for positron emission tomography of P-glycoprotein dysfunction
   Xia Liu et al, 2024, Bioorganic & Medicinal Chemistry Letters CrossRef
3. Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances
   Run-Ze Chen et al, 2021, Frontiers in Oncology CrossRef
4. Ultrasmall nanostructured drug based pH-sensitive liposome for effective treatment of drug-resistant tumor
   Yanyan Li et al, 2019, Journal of Nanobiotechnology CrossRef
5. Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux
   Clarissa Willers et al, 2019, Journal of Cancer Research and Clinical Oncology CrossRef
6. Pristimerin in Oxidative Stress and Use in Cancer
   Ana Carolina B. da C. Rodrigues et al, 2022, Handbook of Oxidative Stress in Cancer: Therapeutic Aspects CrossRef
7. SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer
   Zhen Zheng et al, 2023, Functional & Integrative Genomics CrossRef
8. Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies
   Kirti Prabhu et al, 2024, Pharmaceuticals CrossRef
9. ABCB1 Mediates Cabazitaxel–Docetaxel Cross-Resistance in Advanced Prostate Cancer
   Alan P. Lombard et al, 2017, Molecular Cancer Therapeutics CrossRef
10. Pristimerin in Oxidative Stress and Use in Cancer
    Ana Carolina B. da C. Rodrigues et al, 2021, Handbook of Oxidative Stress in Cancer: Therapeutic Aspects CrossRef
11. Enhancing conventional chemotherapy drug cisplatin-induced anti-tumor effects on human gastric cancer cells both in vitro and in vivo by Thymoquinone targeting PTEN gene
    Jingjing Ma et al, 2017, Oncotarget CrossRef